The question comes up constantly in hormone optimisation consultations: if HGH is what you actually want more of, why not just take HGH directly? Why use a peptide that stimulates your pituitary to make it, rather than simply replacing it?
The answer is nuanced, and most articles get it wrong in one direction or another, either overselling sermorelin as clearly superior or dismissing peptide therapy as an inferior compromise. The honest answer is that the right choice depends on specific clinical circumstances, and there are cases where direct HGH is more appropriate.
The fundamental mechanism difference
Pharmaceutical HGH (somatropin) is a lab-manufactured version of the 191-amino acid growth hormone molecule. It enters the bloodstream directly, binds GH receptors in peripheral tissues, and raises GH and IGF-1 regardless of what the pituitary is doing. It bypasses the body's own GH production system entirely.
Sermorelin is the first 29 amino acids of growth hormone-releasing hormone, the shortest fragment with full biological activity at the GHRH receptor. It stimulates the pituitary to produce and release its own GH. The pituitary's somatostatin feedback mechanism remains intact, if GH levels get too high, somatostatin suppresses further release. Sermorelin works within the body's regulatory architecture rather than overriding it.
The somatostatin feedback brake that remains active with sermorelin is the key safety advantage. With pharmaceutical HGH, there is no endogenous regulatory mechanism, you get the dose you inject regardless of baseline levels. With sermorelin, the pituitary self-regulates. This makes accidental overdose or supraphysiological GH levels significantly less likely with sermorelin at standard clinical doses.
The flip side: if your pituitary is severely compromised, as in adult-onset GH deficiency from a pituitary tumour or radiation, sermorelin cannot work because there is nothing left to stimulate. This is the primary clinical indication where direct HGH is clearly preferable.
Evidence, where each compound has the stronger data
Pharmaceutical HGH has the deeper evidence base. FDA-approved since 1985 and used clinically for four decades, the body composition evidence, lean mass increases, visceral fat reduction, bone density improvement, is established in large adult clinical trials. The side effect profile is well-characterised. If you want controlled evidence for body composition changes from GH axis manipulation, HGH has it.
Sermorelin was FDA-approved in 1997 as Geref for paediatric GH deficiency and discontinued in 2008 for commercial rather than safety reasons. The adult body composition evidence rests primarily on the Khorram et al. study: 19 men, 16 weeks, single-blind, showing +1.26 kg lean mass. Thin by Phase 3 standards. The stronger GHRH analogue evidence comes from tesamorelin, FDA-approved with full Phase 3 trials, which works through the same mechanism.
| Factor | Sermorelin | Pharmaceutical HGH |
|---|---|---|
| Mechanism | Stimulates pituitary GH release | Replaces GH directly |
| Feedback regulation | Somatostatin brake intact | None, bypasses regulation |
| FDA status | Prior approval, compoundable | FDA approved, multiple indications |
| Adult body comp evidence | Thin, 19-subject study | Established Phase 3 trials |
| Water retention risk | Lower | Higher at supraphysiological doses |
| Carpal tunnel risk | Lower | Common side effect at performance doses |
| Acromegaly risk | Very low, self-regulating | Risk with chronic overdose |
| Cost monthly | ~$150–300 compounded | $500–1,500+ brand name |
| Pituitary requirement | Functioning pituitary required | Works regardless of pituitary function |
| WADA status | Prohibited | Prohibited |
Safety profile, where sermorelin genuinely wins
The most common side effects of pharmaceutical HGH at therapeutic doses: water retention and oedema (very common, often dose-limiting), carpal tunnel syndrome, joint pain, and, at chronic supraphysiological doses, risk of insulin resistance. These are dose-dependent effects that become more problematic at the higher doses used in performance contexts versus the lower replacement doses for diagnosed GH deficiency.
Sermorelin's side effects at standard clinical doses are considerably milder: injection site reactions, transient flushing, occasional headache. The somatostatin feedback mechanism limits how far GH can be pushed, which also limits the side effects. The practical implication: sermorelin is more appropriate for long-term optimisation protocols. HGH is more appropriate when clinical deficiency requires reliable, measurable hormone replacement that a compromised pituitary cannot provide.
When pharmaceutical HGH is actually the better choice
There are clear clinical circumstances where direct HGH is more appropriate than sermorelin:
Diagnosed adult GH deficiency confirmed by stimulation testing in a patient with documented pituitary pathology. The pituitary is often unable to respond to GHRH stimulation. FDA-approved somatropin is the appropriate treatment and typically covered by insurance with documented deficiency.
When rapid, measurable GH elevation is required, for patients where clinical improvement requires reliable, controlled GH replacement rather than physiological stimulation, direct HGH provides more predictable dose-response relationships.
Paediatric growth hormone deficiency, current standard of care is recombinant HGH. Sermorelin (Geref) was used historically but was commercially discontinued.
The cost reality in 2026
Brand-name somatropin costs $500–1,500+ monthly and is typically covered by insurance only for diagnosed GH deficiency with appropriate testing. Without insurance, cost is prohibitive for most patients. Compounded sermorelin at $150–300/month through telehealth providers represents dramatically lower cost access to GH axis support. This cost difference drives much of the clinical preference for sermorelin, not superiority, but accessible risk-benefit for optimisation goals that do not meet the insurance threshold.
The tesamorelin benchmark
If the goal is clinical evidence for GHRH analogue therapy in adults, tesamorelin (Egrifta) has what sermorelin lacks: a full Phase 3 programme with 816 patients, FDA approval for visceral fat reduction, and a randomised controlled trial showing cognitive benefits. For patients where the evidence standard matters and access allows, tesamorelin is the benchmark for this compound class.